Company: MVIS
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009765
Chunk: 133

Company: MICROVISION, INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 133
---
 Options (Subtopic 470-20). The amendments in
this ASU clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for
as an induced conversion. The amendments in this Update are effective for all entities for annual reporting periods beginning after December
15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities that have
adopted the amendments in ASU 2020-06. The ASU is not expected to have a material impact on the Company’s financial statements
or disclosures.

3.
NET LOSS PER SHARE

Basic
net loss per share is calculated using the weighted-average number of common shares outstanding during the period. Diluted net loss per
share is calculated using the weighted-average number of common shares outstanding and the dilutive effect of all potentially dilutive
securities, including common stock equivalents and convertible securities. As the effect of dilutive securities outstanding during the
period is anti-dilutive, diluted net loss per share is equal to basic net loss per share.

The
components of basic and diluted net loss per share are as follows (in thousands, except loss per share data):

 SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE

    Three Months Ended 

    March 31, 

    2025  
    2024 
  
    Numerator: 

    Net loss available for common shareholders - basic and diluted 
    $(28,779) 
    $(26,313)

    Denominator: 

    Weighted-average common shares outstanding - basic and diluted 
     235,933  
     196,748 

    Net loss per share - basic and diluted 
    $(0.12) 
    $(0.13)

For
the three months ended March 31, 2025 and 2024, we excluded the following securities from net loss per share as the effect of including
them would have been anti-dilutive: outstanding options exercisable into a total of 0.7
million and 0.7
million shares of common stock, respectively,
and 12.4
million and 9.2
million nonvested restricted stock units, respectively;
20.5
million and 0.0
million shares of common stock that may be issued
through conversion of the derivative liability, respectively (see Note 6. Notes Payable and Derivative Liability); and 5.8
million and